Fortress Biotech’s Urica expands exclusive license agreement with Fuji Yakuhin

Urica Therapeutics,, a Fortress Biotech subsidiary company, announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin for the development of dotinurad to include the Middle East and North Africa and Turkey territories. The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States, United Kingdom, European Union and Canada. Under the terms of the agreement, the Company acquired exclusive development and marketing rights in MENA and Turkey from Fuji. Fuji is eligible to receive upfront and royalty payments from the Company. Jay D. Kranzler, M.D., Ph.D., Urica’s Chairman and Chief Executive Officer, said, "We continue to have a very collaborative relationship with Fuji and we are pleased to expand the license agreement to include additional territories. MENA and Turkey have a combined population of over 550 million, with limited therapeutic options for the treatment of gout. We expect to leverage the substantial preclinical and clinical data generated to-date and work with local regulatory authorities across the territory to expedite the approval process for dotinurad within these territories in the near-term. We hope to advance these discussions quickly and file the relevant marketing applications as soon as possible."